In-vivo Immunomodulation by Isoprinosine in Patients with the Acquired Immunodeficiency Syndrome and Related Complexes
Authors: MICHAEL H. GRIECO
Journal: Annals of Internal Medicine (1984)

Brief Reports1 August 1984In-vivo Immunomodulation by Isoprinosine in Patients with the Acquired Immunodeficiency Syndrome and Related ComplexesMICHAEL H. GRIECO, M.D., MOHAN M. REDDY, Ph.D., DOLLY MANVARI, M.D., KISHORE K. AHUJA, M.D., MARY L. MORIARTY, B.S.MICHAEL H. GRIECO, M.D.Search for more papers by this author, MOHAN M. REDDY, Ph.D.Search for more papers by this author, DOLLY MANVARI, M.D.Search for more papers by this author, KISHORE K. AHUJA, M.D.Search for more papers by this author, MARY L. MORIARTY, B.S.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-2-206 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptRecently an outbreak of Kaposi's sarcoma and opportunistic infections including Pneumocystis carinii pneumonia has been reported in homosexual men, intravenous drug abusers, Haitian immigrants, and hemophiliacs (1). This acquired immunodeficiency syndrome is characterized by lymphopenia, impaired T lymphocyte function, and reversal of helper (OKT4) to suppressor (OKT8) lymphocyte subpopulations. Patients in implicated risk groups with unexplained symptoms such as persistent lymphadenopathy and diarrhea, fever, or progressive weight loss have complexes related to the syndrome (2).Isoprinosine is a synthetic molecular complex formed from inosine and the p-acetamidobenzoic acid salt of N,N-dimethyl amino-2 propanol in a 1 to 3 molar ratio....References1. GOTTLIEBGROOPMANWEINSTEINFAHEYDETELS MJWJR. The acquired immunodeficiency syndrome. Ann Intern Med. 1983;99:208-20. LinkGoogle Scholar2. HADDENGINER-SOROLLA JA. Isoprinosine and NPT 15,392: modulators of lymphocyte and macrophage development and function. In: HERSH EM, CHIRIGOS MA, MASTRANGELO MJ, eds. Augmenting Agents in Cancer Therapy. New York: Raven Press; 1981:497-522. Google Scholar3. WYBRANFAMAEYGORTZDABMALFROOTAPPLEBOOM JJRIAT. Inosiplex (Isoprinosine): a review of its immunological and clinical effects of disease. Adv Pharmacol Therapeut II. 1982;6:123-31. Google Scholar4. MORINBALLET AJ. A recent overview on in vitro and in vivo immunological activities of methisoprinol. Allergol Immunopathol. 1982;10:109-14. MedlineGoogle Scholar5. HADDADRISK FW. Isoprinosine treatment in 18 patients with subacute sclerosing panencephalitis: a controlled study. Ann Neurol. 1980;7:185-8. CrossrefMedlineGoogle Scholar6. FRIDMANCALLEMORIN HRA. Double-blind study of Isoprinosine influence on immune parameters in solid tumor-bearing patients treated by radiotherapy. Int J Immunopharmacol. 1980;2:194. CrossrefGoogle Scholar7. WYBRANFAMAEYAPPLEBOOM JJT. Inosiplex: a novel treatment in rheumatoid arthritis. J Rheumatol. 1981;8:643-6. MedlineGoogle Scholar8. PRINCEGOTTLIEBKERMANI-ARABFAHEY HMVL. Interleukin-2 (IL-2) and IL-2 receptor: relationship to defective T cell proliferation in acquired immune deficiency syndrome [Abstract]. Fed Proc. 1983;42:1334. Google Scholar9. CIOBANUWELTEKRUGER NKG. Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin-2. J Clin Immunol. 1983;3:332-40. CrossrefMedlineGoogle Scholar10. TSANGFUDENBERGGALBRAITH KHG. In vitro augmentation of interleukin-2 production and lymphocytes with the TAC antigen marker in patients with AIDS [Letter]. N Engl J Med. 1984;310:987. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: St. Luke's-Roosevelt Hospital Center New York, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByImmunomodulatory Drugs of Relevance to the Management of Microbial InfectionsCurrent status of immunotherapy of patients with HIV-infectionInosine pranobex in the treatment of HIV infection: A reviewInosine Pranobex — Is a Single Positive Trial Enough?Therapeutic ImmunomodulationInhibition of Growth of HIV by Human Natural Interferon In VitroTherapy of Human Immunodeficiency Virus InfectionsAcquired Immunodeficiency Syndrome (AIDS)Acquired Immune Deficiency SyndromeImmunoreconstitution of T-cell impairments in asymptomatic male homosexuals by Thymic Humoral Factor (THF)The Clinical Challenges of AIDS and HIV InfectionBiological Response Modifiers in the Management of Viral InfectionDrug Information Analysis ServiceImmunoregulatory abnormalities in myelodysplastic disordersA double-blind clinical trial of the effects of inosine pranobex in immunodepressed patients with prolonged generalized lymphadenopathyImmunotherapy of Acquired Immune Deficiency Syndrome (AIDS), AIDS-related Complex and Subjects at RiskKaposi's Sarcoma and AIDSEFFECT OF AZIMEXON THERAPY ON HOST DEFENSE PARAMETERS AND DISEASE-ASSOCIATED SYMPTOMS IN THE ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) AND AIDS-RELATED COMPLEX (ARC)Unique T-Cell Immune Abnormalities in the Development of Acquired Immune Deficiency Syndrome (AIDS)Immunotherapy in acquired immune deficiency syndrome and related syndromesImmunologic Reconstitution in the Acquired Immunodeficiency SyndromeH. CLIFFORD LANE, M.D., ANTHONY S. FAUCI, M.D.Recent developments in immunomodulatory therapyLevamisole, Immunostimulation, and the Acquired Immunodeficiency SyndromeNARASIMHA SURAPANENI, M.D., RUKMANI RAGHUNATHAN, M.D., GILDON N. BEALL, M.D., KATHERINE DANIEL, R.N., M.N., THOMAS M. MUNDY, M.D.Potential Usefulness of Isoprinosine as an Immunostimulating Agent in EBV-Associated Disorders: In Vitro Studies 1 August 1984Volume 101, Issue 2Page: 206-207KeywordsAIDSHomosexualsImmunomodulationKaposi sarcomaLymphocytesLymphopeniaOpportunistic infectionsPneumocystis carinii pneumoniaSaltsWeight loss Issue Published: 1 August 1984 PDF DownloadLoading ...